Trade AstraZeneca PLC - GBP - AZNl CFD
Add to favourite- Summary
- Historical Data
Spread | 2.48 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02461% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002692% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.65 | ||||||||
Currency | GBP | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
Prev. Close | 117.1 |
Open | 117.86 |
1-Year Change | 7.53% |
Day's Range | 116.9 - 119.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 11, 2024 | 117.10 | -0.34 | -0.29% | 117.44 | 117.96 | 116.44 |
Oct 10, 2024 | 117.46 | 0.18 | 0.15% | 117.28 | 118.32 | 117.14 |
Oct 9, 2024 | 116.46 | -0.62 | -0.53% | 117.08 | 117.82 | 116.46 |
Oct 8, 2024 | 116.72 | 0.06 | 0.05% | 116.66 | 117.44 | 116.62 |
Oct 7, 2024 | 117.86 | 0.38 | 0.32% | 117.48 | 118.32 | 116.46 |
Oct 4, 2024 | 117.34 | -0.68 | -0.58% | 118.02 | 119.08 | 115.76 |
Oct 3, 2024 | 119.46 | -0.73 | -0.61% | 120.19 | 120.69 | 119.06 |
Oct 2, 2024 | 119.46 | 1.58 | 1.34% | 117.88 | 119.95 | 117.74 |
Oct 1, 2024 | 117.56 | 1.12 | 0.96% | 116.44 | 117.72 | 115.54 |
Sep 30, 2024 | 115.58 | -0.48 | -0.41% | 116.06 | 117.12 | 115.52 |
Sep 27, 2024 | 115.20 | 0.28 | 0.24% | 114.92 | 117.18 | 114.92 |
Sep 26, 2024 | 116.72 | -0.58 | -0.49% | 117.30 | 117.42 | 114.30 |
Sep 25, 2024 | 115.42 | 1.08 | 0.94% | 114.34 | 115.70 | 112.82 |
Sep 24, 2024 | 112.82 | -2.18 | -1.90% | 115.00 | 116.08 | 112.80 |
Sep 23, 2024 | 115.40 | 0.40 | 0.35% | 115.00 | 117.24 | 115.00 |
Sep 20, 2024 | 115.56 | -2.54 | -2.15% | 118.10 | 119.30 | 115.56 |
Sep 19, 2024 | 118.76 | -0.42 | -0.35% | 119.18 | 120.25 | 118.52 |
Sep 18, 2024 | 118.60 | -0.56 | -0.47% | 119.16 | 119.26 | 118.14 |
Sep 17, 2024 | 119.70 | 0.37 | 0.31% | 119.33 | 120.95 | 119.02 |
Sep 16, 2024 | 118.50 | -0.90 | -0.75% | 119.40 | 120.45 | 118.50 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - GBP Company profile
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
News
Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024US Core CPI tipped to remain unchanged in September
US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.
07:10, 9 October 2024RBNZ expected to deliver “jumbo” rate cut
The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.
08:48, 8 October 2024September Non-Farm Payrolls eases fears of US economic slowdown
Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.
07:44, 8 October 2024Gold's recent story
Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.
15:36, 7 October 2024September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com